Eli Lilly became the second drugmaker this week to sue the U.S. government for rejecting their proposed changes to a program ...

Should you forget Eli Lilly and buy this magnificent biotech instead? Let's find out.

Eli Lilly proposed a plan to ensure 340B entities pay no more than the ceiling price by providing them with cash directly on ...

Lilly follows fellow drugmaker Johnson & Johnson, who sued the Health and Human Services Department on Tuesday, accusing the ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Being started on a smaller dose of the approved early Alzheimer’s therapy Kisunla was found to reduce the risk of ARIA-E on imaging scans.

Move Over, Vial. In a new titration protocol (bottom), one vial of antibody moves from the first dose to the third; total donanemab exposure in the first six months remains identical to the standard ...

Cassava Sciences, Inc. ( NASDAQ: SAVA) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Rick Barry - President & Chief Executive Officer Eric Schoen - Chief Financial Officer ...

In 2023, Aditum’s weight loss biotech Versanis Bio sold to Eli Lilly for up to $1.92 billion in upfront payments and ...

Anavex Life Sciences' (AVXL) stock surged on new Alzheimer's trial data, but data's inconsistency raises concerns, making the ...

Researchers from Eli Lilly & Co. presented the discovery and preclinical characterization of a novel protein tyrosine kinase ...

Delve into Sanofi's "play to win" strategy as investments are ramping up after their consumer health division's divestment.